Drug Database · Clinicians

Tamsulosin

Brands (60) Tamzor, Pimax, Prostanil MR…Show all

US brand (reference label): Tamsulosin hydrochloride; not a Philippine-registered brand.

Alpha-adrenoreceptor antagonist; Alpha-adrenoceptor antagonist; and others PH FDA category

Rx · Prescription drug86 PH productsPNF-listedPhilHealth GAMOT
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 13a5032d-0be1-4001-916e-459f0b1a051d, version date October 27, 2026 (Tamsulosin hydrochloride · Synthon B.V.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14) ] .
  • Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14)]. Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. Tamsulosin hydrochloride capsules are an alpha 1 adrenoceptor antagonist indicated for treatment of the signs and symptoms of benign prostatic hyperplasia (1) Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension (1)

Contraindications

4 CONTRAINDICATIONS Tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. Reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see Adverse Reactions (6.2)]. Contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules (4, 6.2)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened. For those patients who fail to respond to the 0.4 mg dose after 2 to 4 weeks of dosing, the dose of tamsulosin hydrochloride capsules can be increased to 0.8 mg once daily.

Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions (5.2)]. If tamsulosin hydrochloride capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once-daily dose. 0.4 mg once daily taken approximately one-half hour following the same meal each day.

Tamsulosin hydrochloride capsules should not be crushed, chewed or opened. (2) Can be increased to 0.8 mg once daily for patients who fail to respond to the 0.4 mg dose after 2 to 4 weeks of dosing (2) If discontinued or interrupted for several days, therapy should start again with the 0.4 mg once-daily dose (2)

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.6 Renal Impairment Patients with renal impairment do not require an adjustment in tamsulosin hydrochloride capsules dosing. However, patients with end-stage renal disease (CL cr <10 mL/min/1.73 m²) have not been studied [see Clinical Pharmacology (12.3)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment Patients with moderate hepatic impairment do not require an adjustment in tamsulosin hydrochloride capsules dosage. Tamsulosin hydrochloride capsules have not been studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Tamsulosin hydrochloride capsules are not indicated for use in pediatric populations. Efficacy and positive benefit/risk of tamsulosin hydrochloride was not demonstrated in two studies conducted in patients 2 years to 16 years of age with elevated detrusor leak point pressure (>40 cm H 2 O) associated with known neurological disorder (e.g., spina bifida).

Patients in both studies were treated on a weight-based mg/kg schema (0.025 mg, 0.05 mg, 0.1 mg, 0.2 mg, or 0.4 mg tamsulosin hydrochloride) for the reduction in detrusor leak point pressure below 40 cm H 2 O. In a randomized, double-blind, placebo-controlled, 14-week, pharmacokinetic, safety and efficacy study in 161 patients, no statistically significant difference in the proportion of responders was observed between groups receiving tamsulosin hydrochloride and placebo.

In an open-label, 12-month safety study, 87 patients were treated with tamsulosin hydrochloride. The most frequently reported adverse events (≥5%) from the pooled data of both studies were urinary tract infection, vomiting, pyrexia, headache, nasopharyngitis, cough, pharyngitis, influenza, diarrhea, abdominal pain, and constipation.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of subjects (1783) in clinical studies of tamsulosin, 36% were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].

Dosage forms

Philippines

  • Prolonged-release capsule: 200 mcg, 400 mcg
  • Enteric-coated tablet: 200 mcg, 400 mcg
  • Prolonged-release tablet: 200 mcg, 400 mcg
  • Film-coated tablet: 400 mcg
  • Capsule: 400 mcg
  • Modified-release capsule: 400 mcg
  • Sustained-release capsule: 200 mcg, 400 mcg
  • Extended-release tablet: 200 mcg
  • Prolonged-release film-coated tablet: 400 mcg
  • Prolonged-release-capsule: 400 mcg

and 1 more forms; see the products table.

Registered products in the Philippines

86 products registered with the Food and Drug Administration (FDA) Philippines list Tamsulosin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products86
Philippine FDA-registered products for Tamsulosin
Package insert
AlfatamTamsulosin (as hydrochloride)
400 mcg CapsuleAlu/ PVC Blister Pack x 10's (Box of 30's)
Rx
Cadila Healthcare LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-9962
Mar 13, 2027
AmkoprosTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's
Rx
Cooper Pharma LimitedIndia
AMK Pharma International TradingImporter: Ambica International Corporation
DRP-6069-03
Mar 11, 2030
AmsoTamsulosin Hydrochloride
400mcg Prolonged-Release CapsuleAlu-Alu Blister Pack x 10's (Box of 10's and 30's)
Rx
Globela Pharma Pvt. Ltd.India
Biocare Lifesciences, Inc.Trader: AMN Life Science Pvt. Ltd.
DRP-3940
Sep 5, 2027
BettamTamsulosin Hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Sydler Remedies Pvt. Ltd.India
Medinova Pharmaceutical Inc.Importer: S.M.H.P Marketing & ConsultancyTrader: Betam Laboratories Pvt. Ltd.
DRP-12762
Jun 3, 2028
Dellosin ExtTamsulosin Hydrochloride
400 mcg Prolonged-Release TabletAlu/ Alu Blister Pack x 10's (Box of 30’s)
Rx
Magbro Healthcare Pvt. Ltd.India
NAB Trading Corp.Importer: Pharmakon Biotec Inc.
DRP-13519-05
Mar 3, 2028
FloezyTamsulosin Hydrochloride
400 mcg Prolonged Release TabletAlu/PA/Alu/PVC Blister Pack x 10's (Box of 30's)
Rx
SYNTHON HISPANIA, S.L.Spain
METRO DRUG, INC.Importer: MEGA LIFESCIENCES LIMITED INC.Trader: MEGA LIFESCIENCES (AUSTRALIA) PTY. LTD.
DRP-8084
Jan 28, 2029
Freelosin MRTamsulosin hydrochloride
400 mcg Prolonged-Release-CapsuleAlu/Alu Blister Pack x 6's (Box of 30's)
Rx
Aristopharma Ltd.Bangladesh
Amson PharmaceuticalsImporter: Sahar International Trading Inc.
DRP-13026-01
Aug 23, 2027
GilosinTamsulosin
400 mcg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Gijun Trading Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13392-01
Feb 10, 2028
Harnal DTamsulosin hydrochloride
200 mcg TabletAlu-alu blister pack x 14's (Box of 28's)
Rx
TOA Pharmaceuticals Co., Ltd. (Nishihongo Plant)Japan
Zuellig Pharma CorporationImporter: Astellas Pharma Philippines, Inc.
DR-XY34109
Jan 7, 2028
Harnal OcasTamsulosin Hydrochloride
400 mcg Prolonged Release Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's)
Rx
Astellas Pharma Europe B.V.Netherlands
Zuellig Pharma CorporationImporter: Astellas Pharma Philippines, Inc.
DR-XY33041
Feb 26, 2027
LifezulTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Curasave PharmaImporter: Ambica International Corporation
DRP-6069-02
Mar 11, 2030
NeolosinTamsulosin Hydrochloride
200 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-5272-04
Apr 22, 2029
NoneTamsulosin Hydrochloride
200 mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicure Remedies Pvt. Ltd.India
Ritemed Phils., Inc.Importer: Ambica International Corporation
DRP-5529-01
Sep 23, 2029
NoneTamsulosin Hydrochloride
200 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-5272
Apr 22, 2029
NoneTamsulosin Hydrochloride
200 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
PharmaVital Corp.Importer: Ambica International Corporation
DRP-5272-05
Apr 22, 2029
NoneTamsulosin hydrochloride
400 mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicure Remedies Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-4938-01
Nov 19, 2028
NoneTamsulosin hydrochloride
400 mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicure Remedies Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4938-03
Nov 19, 2028
NoneTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Alu Blister pack x 10’s Box of 30's
Rx
Cooper Pharma LimitedIndia
Ritemed Phils., Inc.Importer: Ambica International Corporation
DRP-6069-01
Mar 11, 2030
NoneTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Alu Blister pack x 10’s (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Rose Pharmacy, IncorporatedImporter: Ambica International Corporation
DRP-6069-06
Mar 11, 2030
NoneTamsulosin hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack of 10’s (Box of 30’s)
Rx
Sydler Remedies Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-6372-01
Oct 7, 2030
NoneTamsulosin hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack of 10’s (Box of 30’s)
Rx
Sydler Remedies Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-6372-03
Oct 7, 2030
NoneTamsulosin Hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 7’s (Box of 28's and 98's)
Rx
Stallion Laboratories Pvt. Ltd.India
PharmaVital Corp.Importer: Ambica International Corporation
DRP-8237-03
Jun 18, 2029
NoneTamsulosin Hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 7’s (Box of 28's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-8237-04
Jun 18, 2029
NoneTamsulosin
400 mcg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. LtdIndia
Reta DrugImporter: Teramedix Pharma Trading Inc.
DRP-13392-02
Feb 10, 2028
PimaxTamsulosin Hydrochloride
200mcg Enteric-Coated TabletAlu/PVC Blister Pack X 10's (Box of 30's)
Rx
UNICURE REMEDIES PVT.LTD.India
ECE Pharmaceuticals, Inc.Importer: AAA PHARMA INC.
DR-XY 41055
Jul 20, 2027
PimaxTamsulosin Hydrochloride
400mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicare Remedies Pvt. LimitedIndia
ECE Pharmaceuticals, Inc.,Importer: AAA Pharma, Inc.,
DR-XY36548
Aug 25, 2029
PrositamTamsulosin Hydrochloride
400 mcg CapsuleAlu-Alu Blister Packs of 10's (Box of 30's and 100's)
Rx
Ratnatris Pharmaceuticals Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-18165
May 21, 2031
ProstalifeTamsulosin Hydrochloride
400 mcg Modified-Release CapsuleAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Zim Laboratories Ltd.India
Macropharma CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd.
DRP-4930
Nov 15, 2028
Prostanil MRTamsulosin hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 6's (Box of 30's)
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading, Inc.
DR-XY45993
Aug 23, 2027
Prostanil MRTamsulosin hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 6's (Box of 30's)
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading, Inc.
DRP-13026
Aug 23, 2027
Prostasaph-400Tamsulosin Hydrochloride
400 mcg Enteric Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.Importer: Ollen Pharma Trading Inc.
DRP-10996-01
Apr 15, 2030
ProstazinTamsulosin hydrochloride
400 mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicure Remedies Pvt. Ltd.India
Labmate Pharma Inc.Importer: Ambica International Corporation
DRP-4938-02
Nov 19, 2028
ProstulaxTamsulosin Hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Sydler Remedies Pvt. Ltd.India
Trumed PharmaceuticalsImporter: S.M.H.P Marketing & ConsultancyTrader: Betam Laboratories Pvt. Ltd.
DRP-12762-1
Jun 3, 2028
ProzelaxTamsulosin Hydrochloride
200 mcg Sustained-Release CapsuleBlister Foil in Aluminum Pouch x 14's (Box of 28's)
Rx
Stand Chem. & Pharma Co., Ltd (Plant II)China
UNILAB, INC.
DR-XY34655
Jun 16, 2028
ProzelaxTamsulosin Hydrochloride
400 mcg CapsuleAlu/PVC/PVDC blister pack x 10's (box of 30's)
Rx
UNILAB, Inc.Philippines
—
DR-XY40807
Oct 14, 2027
Proztab ForteTamsulosin hydrochloride
400 mcg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
Rx
UNICURE REMEDIES PVT. LTD.India
TGP PHARMA INC.Importer: NEXT CHEMICAL ENTERPRISES
DRP-4194-01
Aug 3, 2027
Saphbph-Ge400Tamsulosin Hydrochloride
400 mcg Enteric Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s and 100’s)
Rx
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-18553
Jul 30, 2031
SultamTamsulosin hydrochloride
200 mcg Enteric-Coated TabletAlu/Clear PVC blister pack x l0's (Box of 100's)
Rx
UNICURE REMEDIES PVT. LTD.India
NEXT CHEMICAL ENTERPRISES
DRP-4220
Aug 3, 2027
SultamTamsulosin hydrochloride
400 mcg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
Rx
UNICURE REMEDIES PVT. LTD.India
Importer: NEXT CHEMICAL ENTERPRISES
DRP-4194
Aug 3, 2027
Susaphtam-400Tamsulosin hydrochloride
400 mcg Prolonged Release CapsuleAlu/Clear PVC Blister pack x 10's in aluminum pouch (Box of 10's)
Rx
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-14513
Oct 18, 2028
TamdomeTamsulosin Hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-14512
Sep 26, 2028
TamloTamsulosin hydrochloride
400 mcg Modified-Release CapsuleTransparent PVDC (Alu foil blister x 10's) (Box 30's)
Rx
World Medicine İlaç Sanayi ve Ticaret A.Ş.Turkey
Orange Biotec Inc.
DRP-15872
Oct 1, 2029
TamlozulTamsulosin Hydrochloride
200 mcg Enteric Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100's)
Rx
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences Inc.
DRP-12004-01
May 30, 2027
Tamprost 0.4Tamsulosin Hydrochloride
400 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Sydler Remedies Pvt. LimitedIndia
Medethix IInc.Importer: I.E. Medica, Inc.
DRP-6526-02
Aug 27, 2031
Tamsaph-200Tamsulosin Hydrochloride
200 mcg Enteric Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-12004
May 30, 2027
Tamsia 0.4Tamsulosin hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack of 10’s Box of 30’s
Rx
Sydler Remedies Pvt. Ltd.India
Scriptmed, Inc.Importer: Ambica International Corporation
DRP-6372
Oct 7, 2030
TamsodixTamsulosin
400 mcg Prolonged-Release TabletAlu-Alu Blister Pack X 10's (Box of 30's)
Rx
Magbro Healthcare Pvt., Ltd.India
Euroasia Pharmaceuticals, Inc.Importer: Teramedix Pharma Trading Inc.
DRP-13392-03
Feb 10, 2028
TamsolinTamsulosin hydrochloride
400 mcg Modified-Release CapsuleAlu/ PVDC Blister Pack x 10’s (Box of 10’s)
Rx
Getz Pharma (Pvt.), Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DR-XY38119
Jun 23, 2031
TamsonTamsulosin Hydrochloride
400 mcg Prolonged Release TabletIn a Box of 3 Alu-Alu Blister Pack x 10’s
Rx
Steril-Gene Life Sciences (P) LTD.India
999 Seth Pharmaceutical Inc.Importer: Ambica International CorporationTrader: Swati Spentose Pvt. Ltd.
DRP-6481-01
Jun 4, 2037
TamsudinTamsulosin Hydrochloride
200 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-5272-01
Apr 22, 2029
TamsufarTamsulosin Hydrochloride
400 mcg Prolonged-Release TabletAlu/Alu blister pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-13519
Mar 3, 2028
TamsukemTamsulosin Hydrochloride
400 mcg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc.
DRP-13519-01
Mar 3, 2028
Tamsulon-XLTamsulosin Hydrochloride
200 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-5272-02
Apr 22, 2029
Tamsulon-XLTamsulosin Hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 7’s (Box of 28's and 98's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-8237
Jun 18, 2029
TamsumaxTamsulosin Hydrochloride
200 mcg Sustained-Release CapsuleClear PVC/PVDC-Alu Blister Pack x 10's (Box of 30's)
Rx
Hangzhou Conba Pharmaceutical Co., Ltd.China
Pharmabest Incorporated
DR-XY40607
Feb 3, 2027
TamsumaxTamsulosin Hydrochloride
400 mcg Sustained-Release CapsuleClear PVC/Alu Blister Pack x 10's (Box of 30's)
Rx
Hangzhou Conba Pharmaceutical Co., Ltd.China
Pharmabest Incorporated
DR-XY40606
Feb 3, 2027
TamsunavTamsulosin Hydrochloride
400 mcg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Rexmed Pharmaceutical SalesImporter: Pharmakon Biotec Inc.
DRP-13519-02
Mar 3, 2028
TAMSUREDTamsulosin Hydrochloride
400 mcg Enteric Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
Sai Parenterals Ltd.India
777 RED PHARMA INC.Importer: Ollen Pharma Trading Inc.
DRP-10996-02
Apr 15, 2030
TamsusaveTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Alu Blister pack x 10’s (Box of 30’s)
Rx
Cooper Pharma LimitedIndia
Curasave PharmaImporter: Ambica International Corporation
DRP-6069-05
Mar 11, 2030
TamsuzenTamsulosin Hydrochloride
400 mcg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Janamed CorporationImporter: Pharmakon Biotec Inc.
DRP-13519-04
Mar 3, 2028
TamsycareTamsulosin Hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister pack x 7’s (Box of 28’s and 98's)
Rx
Stallion Laboratories Pvt. Ltd.India
Medcare PharmaceuticalsImporter: Ambica International Corporation
DRP-8237-01
Jun 18, 2029
TamtessTamsulosin Hydrochloride
400 mcg Prolonged Release TabletIn a Box of 3 Alu-Alu Blister Pack x 10’s
Rx
Steril-Gene Life Sciences (P) LimitedIndia
Vitalife Pharma & Medical Supply Inc.Importer: Ambica International CorporationTrader: Swati Spentose Pvt. Ltd.
DRP-6481-02
Jan 25, 2038
TamulsinTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Cooper Pharma Ltd.India
D & G PharmaImporter: Ambica International Corporation
DRP-6069-04
Mar 11, 2030
Tamysin 0.2Tamsulosin Hydrochloride
200 mcg Prolonged Release TabletIn a box of 3 alu-alu blister pack x 10’s Not Applicable
Rx
Steril-Gene Life Sciences (P) LimitedIndia
Ambica International CorporationTrader: Swati Spentose Pvt. Ltd.
DRP-6482
Jan 25, 2038
Tamysin 0.4Tamsulosin Hydrochloride
400 mcg Prolonged Release TabletIn a box of 3 alu-alu blister pack x 10’s
Rx
Steril-Gene Life Sciences (P) LimitedIndia
Ambica International CorporationTrader: Swati Spentose Pvt. Ltd.
DRP-6481
Jan 25, 2038
TamzorTamsulosin Hydrochloride
200 mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicure Remedies Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Ambica International Corporation
DRP-5529-03
Sep 23, 2029
TamzorTamsulosin Hydrochloride
200 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Ambica International Corporation
DRP-5272-03
Apr 22, 2029
TamzorTamsulosin Hydrochloride
200 mcg Prolonged Release TabletIn a box of 3 Alu-Alu Blister Pack x 10’s N/A
Rx
Steril-Gene Life Sciences (P) LimitedIndia
The Cathay Drug Co., Inc.Importer: Ambica International CorporationTrader: Swati Spentose Pvt. Ltd.
DRP-6482-01
Jun 17, 2037
TamzorTamsulosin hydrochloride
400 mcg Prolonged-Release CapsuleAlu/ Alu Blister Pack x 10's (Box of 10's)
Rx
GLOBELA PHARMA PRIVATE LIMITEDIndia
THE CATHAY DRUG CO., INC.Importer: BIOCARE LIFESCIENCES, INC.
DRP-3940-01
Sep 5, 2027
TamzorTamsulosin Hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack x 7's (Box of 28’s)
Rx
Stallion Laboratories Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Ambica International Corporation
DRP-8237-02
Jun 18, 2029
TamzuTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Clear PVC Blister Pack x 14's Box of 28's
Rx
General Pharmaceuticals Ltd. (Unit I)Bangladesh
Beracah Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-3818-02
Jun 29, 2027
TemsolTamsulosin hydrochloride
400 mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicure Remedies Pvt. Ltd.India
Innogen Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-4938
Nov 19, 2028
Temsol 200Tamsulosin Hydrochloride
200 mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicure Remedies Pvt. Ltd.India
Innogen Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-5529
Sep 23, 2029
ToreaseTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Cooper Pharma LimitedIndia
Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-6069-07
Mar 11, 2030
TozulTamsulosin Hydrochloride
400 mcg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-13519-03
Mar 3, 2028
UnbrandedTamsulosin Hydrochloride
200 mcg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Unicure Remedies Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-5529-02
Sep 23, 2029
UnbrandedTamsulosin Hydrochloride
400 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 10's)
Rx
Sydler Remedies Pvt. LimitedIndia
Actimed, Inc.Importer: I.E. Medica, Inc.
DRP-6526
Feb 15, 2031
UnbrandedTamsulosin Hydrochloride
400 mcg Prolonged Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Sydler Remedies Pvt. LimitedIndia
Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc.
DRP-6526-01
Aug 27, 2031
UreazyTamsulosin
400 mcg Prolonged-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
MAGBRO HEALTHCARE PVT. LTD.India
TERAMEDIX PHARMA TRADING INC.
DRP-13392
Feb 10, 2028
UrilaxTamsulosin (as Hydrochloride)
200 mcg Extended Release TabletAlu-Alu Blister Pack x 10's (Box of 30's)
Rx
Kyung Dong Pharma Co. Ltd.Republic of Korea
Littman Drug Corporation
DRP-3897
Mar 29, 2031
URILAXTamsulosin hydrochloride
400 mcg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
Rx
UNICURE REMEDIES PVT. LTD.India
LITTMAN DRUG CORPORATIONImporter: NEXT CHEMICAL ENTERPRISES
DRP-4194-03
Aug 3, 2027
Urimax 400Tamsulosin hydrochloride
400 mcg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
UNICURE REMEDIES PVT. LTD.India
Importer: NEXT CHEMICAL ENTERPRISESTrader: QUALIMED PHARMA INC.
DRP-4194-02
Aug 3, 2027
UritamTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu/Alu Blister pack x 10’s Box of 30's
Rx
Cooper Pharma LimitedIndia
Genace Pharma DistributorImporter: Ambica International Corporation
DRP-6069
Mar 11, 2030
UrolosinTamsulosin Hydrochloride
400 mcg Film-Coated TabletAlu Clear/PVC Blister Pack x 14's (Box of 28's)
Rx
General Pharmaceuticals Ltd. (Unit I)Bangladesh
A-Z Market Enterprise Developers IncImporter: Ambica International Corporation
DRP-3818
Jun 29, 2027
UrotosinTamsulosin hydrochloride
400 mcg Prolonged-Release CapsuleAlu/Alu Blister Pack of 10’s (Box of 30’s)
Rx
Sydler Remedies Pvt. Ltd.India
PPAN TradingImporter: Ambica International Corporation
DRP-6372-02
Oct 7, 2030
YulosinTamsulosin (as hydrochloride)
400 mcg Prolonged Release TabletAlu-PVC/PVDC Blister Pack x 10’s (Box of 30’s)
Rx
Kopran LimitedIndia
Triple Tact Import & Export Corp.
DRP-18162
May 20, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Capsule: 0.4 mg, olive green opaque cap and an orange opaque body. The cap is imprinted with the code "TSL 0.4" in black ink. Capsules: 0.4 mg (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Advise patients about the possibility of symptoms related to postural hypotension and to avoid situations where injury could result should syncope occur (5.1)
  • Should not be used in combination with strong inhibitors of CYP3A4. Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (5.2, 7.1, 12.3)
  • Should not be used in combination with other alpha adrenergic blocking agents (5.2, 7.2, 12.3)
  • Exercise caution with concomitant administration of warfarin (5.2, 7.4, 12.3)
  • Advise patients about the possibility and seriousness of priapism (5.3)
  • Intraoperative Floppy Iris Syndrome has been observed during cataract and glaucoma surgery in some patients. Advise patients considering cataract or glaucoma surgery to tell their ophthalmologist that they have taken tamsulosin hydrochloride capsules. (5.5)
  • Advise patients to be screened for the presence of prostate cancer prior to treatment and at regular intervals afterwards (5.4)
5.1 Orthostasis

5.1 Orthostasis The signs and symptoms of orthostasis (postural hypotension, dizziness, and vertigo) were detected more frequently in tamsulosin hydrochloride capsule-treated patients than in placebo recipients. As with other alpha adrenergic blocking agents there is a potential risk of syncope [see Adverse Reactions (6.1)].

Patients beginning treatment with tamsulosin hydrochloride capsules should be cautioned to avoid situations in which injury could result should syncope occur.

5.2 Drug Interactions

5.2 Drug Interactions Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Tamsulosin hydrochloride capsules should not be used in combination with other alpha adrenergic blocking agents [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].

Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].

Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)].

5.3 Priapism Rarely (probably less than 1 in 50,000 patients)

5.3 Priapism Rarely (probably less than 1 in 50,000 patients), tamsulosin, like other alpha 1 antagonists, has been associated with priapism (persistent painful penile erection unrelated to sexual activity). Because this condition can lead to permanent impotence if not properly treated, patients must be advised about the seriousness of the condition.

5.4 Screening for Prostate Cancer

5.4 Screening for Prostate Cancer Prostate cancer and BPH frequently coexist; therefore, patients should be screened for the presence of prostate cancer prior to treatment with tamsulosin hydrochloride capsules and at regular intervals afterwards.

5.5 Intraoperative Floppy Iris Syndrome

5.5 Intraoperative Floppy Iris Syndrome Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin hydrochloride capsules [see Adverse Reactions (6.2)]. Most reports were in patients taking the alpha 1 blocker when IFIS occurred, but in some cases, the alpha 1 blocker had been stopped prior to surgery.

In most of these cases, the alpha 1 blocker had been stopped recently prior to surgery (2 to 14 days), but in a few cases, IFIS was reported after the patient had been off the alpha 1 blocker for a longer period (5 weeks to 9 months). IFIS is a variant of small pupil syndrome and is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs and potential prolapse of the iris toward the phacoemulsification incisions.

The patient's ophthalmologist should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. IFIS may increase the risk of eye complications during and after the operation. The benefit of stopping alpha 1 blocker therapy prior to cataract or glaucoma surgery has not been established.

The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.

5.6 Sulfa Allergy

5.6 Sulfa Allergy In patients with sulfa allergy, allergic reaction to tamsulosin hydrochloride capsules has been rarely reported. If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules.

Drug interactions

Drug interactions (US label) US FDA label
  • Tamsulosin hydrochloride capsules 0.4 mg should not be used with strong inhibitors of CYP3A4 (e.g., ketoconazole). Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, or in patients known to be CYP2D6 poor metabolizers, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg). (5.2, 7.1, 12.3)
  • Concomitant use of PDE5 inhibitors with tamsulosin can potentially cause symptomatic hypotension (5.2, 7.3, 12.3)
7.1 Cytochrome P450 Inhibition Strong and Moderate

7.1 Cytochrome P450 Inhibition Strong and Moderate Inhibitors of CYP3A4 or CYP2D6 Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in an increase in the C max and AUC of tamsulosin by a factor of 2.2 and 2.8, respectively [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of tamsulosin hydrochloride capsules have not been evaluated [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) resulted in an increase in the C max and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM). Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when tamsulosin hydrochloride capsules 0.4 mg are co-administered with strong CYP3A4 inhibitors in CYP2D6 PMs, tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

The effects of concomitant administration of a moderate CYP2D6 inhibitor (e.g., terbinafine) on the pharmacokinetics of tamsulosin hydrochloride capsules have not been evaluated [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. The effects of co-administration of both a CYP3A4 and a CYP2D6 inhibitor with tamsulosin hydrochloride capsules have not been evaluated.

However, there is a potential for significant increase in tamsulosin exposure when tamsulosin hydrochloride capsules 0.4 mg are co-administered with a combination of both CYP3A4 and CYP2D6 inhibitors [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. Cimetidine Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of tamsulosin hydrochloride, which resulted in a moderate increase in tamsulosin hydrochloride AUC (44%) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

7.2 Other Alpha Adrenergic Blocking Agents

7.2 Other Alpha Adrenergic Blocking Agents The pharmacokinetic and pharmacodynamic interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents have not been determined; however, interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents may be expected [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

7.3 PDE5 Inhibitors

7.3 PDE5 Inhibitors Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride capsules are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

7.4 Warfarin

7.4 Warfarin A definitive drug-drug interaction study between tamsulosin hydrochloride and warfarin was not conducted. Results from limited in vitro and in vivo studies are inconclusive. Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

7.5 Nifedipine, Atenolol, Enalapril

7.5 Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see Clinical Pharmacology (12.3)].

7.6 Digoxin and Theophylline

7.6 Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3)].

7.7 Furosemide

7.7 Furosemide Tamsulosin hydrochloride capsules had no effect on the pharmacodynamics (excretion of electrolytes) of furosemide. While furosemide produced an 11% to 12% reduction in tamsulosin hydrochloride C max and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the tamsulosin hydrochloride capsules dosage [see Clinical Pharmacology (12.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6 as well as via some minor participation of other CYP isoenzymes.

Drug Interactions Cytochrome P450 inhibition Strong and moderate inhibitors of CYP3A4 or CYP2D6 The effects of ketoconazole (a strong inhibitor of CYP3A4) at 400 mg once daily for 5 days on the pharmacokinetics of a single tamsulosin hydrochloride capsule 0.4 mg dose was investigated in 24 healthy volunteers (age range 23 to 47 years).

The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of tamsulosin hydrochloride capsules have not been evaluated [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] .

The effects of paroxetine (a strong inhibitor of CYP2D6) at 20 mg once daily for 9 days on the pharmacokinetics of a single tamsulosin hydrochloride capsule 0.4 mg dose was investigated in 24 healthy volunteers (age range 23 to 47 years).

A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM).

A fraction of the population (about 7% of Caucasians and 2% of African Americans) are CYP2D6 PMs.

Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when tamsulosin hydrochloride capsules 0.4 mg are co-administered with strong CYP3A4 inhibitors in CYP2D6 PMs, tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] .

The effects of concomitant administration of a moderate CYP2D6 inhibitor (e.g., terbinafine) on the pharmacokinetics of tamsulosin hydrochloride capsules have not been evaluated [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] .

Adverse reactions

Adverse reactions (US label) US FDA label
  • The most common adverse events (≥2% of patients and at a higher incidence than placebo) with the 0.4 mg dose or 0.8 mg dose were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, cough increased, somnolence, nausea, sinusitis, insomnia, libido decreased, tooth disorder, and blurred vision (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Synthon at 919-493-6006 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The incidence of treatment-emergent adverse events has been ascertained from six short-term U.S. and European placebo-controlled clinical trials in which daily doses of 0.1 to 0.8 mg tamsulosin hydrochloride capsules were used.

These studies evaluated safety in 1783 patients treated with tamsulosin hydrochloride capsules and 798 patients administered placebo. Table 1 summarizes the treatment-emergent adverse events that occurred in ≥2% of patients receiving either tamsulosin hydrochloride capsules 0.4 mg or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S. trials (US92-03A and US93-01) conducted in 1487 men.

Table 1: Treatment-Emergent A treatment-emergent adverse event was defined as any event satisfying one of the following criteria: The adverse event occurred for the first time after initial dosing with double-blind study medication;The adverse event was present prior to or at the time of initial dosing with double-blind study medication and subsequently increased in severity during double-blind treatment; or The adverse event was present prior to or at the time of initial dosing with double-blind study medication, disappeared completely, and then reappeared during double-blind treatment. Adverse Events Occurring in ≥2% of Tamsulosin Hydrochloride Capsules or Placebo Patients in Two U.S.

Short-Term Placebo-Controlled Clinical Studies BODY SYSTEM/ ADVERSE EVENT TAMSULOSIN HYDROCHLORIDE CAPSULES GROUPS PLACEBO 0.4 mg n=502 0.8 mg n=492 n=493 BODY AS WHOLE Headache 97 (19.3%) 104 (21.1%) 99 (20.1%) Infection Coding preferred terms also include cold, common cold, head cold, flu, and flu-like symptoms. 45 (9.0%) 53 (10.8%) 37 (7.5%) Asthenia 39 (7.8%) 42 (8.5%) 27 (5.5%) Back pain 35 (7.0%) 41 (8.3%) 27 (5.5%) Chest pain 20 (4.0%) 20 (4.1%) 18 (3.7%) NERVOUS SYSTEM Dizziness 75 (14.9%) 84 (17.1%) 50 (10.1%) Somnolence 15 (3.0%) 21 (4.3%) 8 (1.6%) Insomnia 12 (2.4%) 7 (1.4%) 3 (0.6%) Libido decreased 5 (1.0%) 10 (2.0%) 6 (1.2%) RESPIRATORY SYSTEM Rhinitis Coding preferred terms also include nasal congestion, stuffy nose, runny nose, sinus congestion, and hay fever. 66 (13.1%) 88 (17.9%) 41 (8.3%) Pharyngitis 29 (5.8%) 25 (5.1%) 23 (4.7%) Cough increased 17 (3.4%) 22 (4.5%) 12 (2.4%) Sinusitis 11 (2.2%) 18 (3.7%) 8 (1.6%) DIGESTIVE SYSTEM Diarrhea 31 (6.2%) 21 (4.3%) 22 (4.5%) Nausea 13 (2.6%) 19 (3.9%) 16 (3.2%) Tooth disorder 6 (1.2%) 10 (2.0%) 7 (1.4%) UROGENITAL SYSTEM Abnormal ejaculation 42 (8.4%) 89 (18.1%) 1 (0.2%) SPECIAL SENSES Blurred vision 1 (0.2%) 10 (2.0%) 2 (0.4%) Signs and Symptoms of Orthostasis In the two U.S. studies, symptomatic postural hypotension was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and by no patients in the placebo group. Syncope was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and 0.6% of patients (3 of 493) in the placebo group.

Dizziness was reported by 15% of patients (75 of 502) in the 0.4 mg group, 17% of patients (84 of 492) in the 0.8 mg group, and 10% of patients (50 of 493) in the placebo group. Vertigo was reported by 0.6% of patients (3 of 502) in the 0.4 mg group, 1% of patients (5 of 492) in the 0.8 mg group, and by 0.6% of patients (3 of 493) in the placebo group.

Multiple testing for orthostatic hypotension was conducted in a number of studies. Such a test was considered positive if it met one or more of the following criteria: (1) a decrease in systolic blood pressure of ≥20 mmHg upon standing from the supine position during the orthostatic tests; (2) a decrease in diastolic blood pressure ≥10 mmHg upon standing, with the standing diastolic blood pressure <65 mmHg during the orthostatic test; (3) an increase in pulse rate of ≥20 bpm upon standing with a standing pulse rate ≥100 bpm during the orthostatic test; and (4) the presence of clinical symptoms (faintness, lightheadedness/lightheaded, dizziness, spinning sensation, vertigo, or postural hypotension) upon standing during the orthostatic test.

Following the first dose of double-blind medication in Study 1, a positive orthostatic test result at 4 hours post dose was observed in 7% of patients (37 of 498) who received tamsulosin hydrochloride capsules 0.4 mg once daily and in 3% of the patients (8 of 253) who received placebo. At 8 hours post dose, a positive orthostatic test result was observed for 6% of the patients (31 of 498) who received tamsulosin hydrochloride capsules 0.4 mg once daily and 4% (9 of 250) who received placebo (Note: patients in the 0.8 mg group received 0.4 mg once daily for the first week of Study 1).

In Studies 1 and 2, at least one positive orthostatic test result was observed during the course of these studies for 81 of the 502 patients (16%) in the tamsulosin hydrochloride capsules 0.4 mg once-daily group, 92 of the 491 patients (19%) in the tamsulosin hydrochloride capsules 0.8 mg once-daily group, and 54 of the 493 patients (11%) in the placebo group. Because orthostasis was detected more frequently in tamsulosin hydrochloride capsule-treated patients than in placebo recipients, there is a potential risk of syncope [see Warnings and Precautions (5.1)].

Abnormal Ejaculation Abnormal ejaculation includes ejaculation failure, ejaculation disorder, retrograde ejaculation, and ejaculation decrease. As shown in Table 1, abnormal ejaculation was associated with tamsulosin hydrochloride capsules administration and was dose-related in the U.S. studies. Withdrawal from these clinical studies of tamsulosin hydrochloride capsules because of abnormal ejaculation was also dose-dependent, with 8 of 492 patients (1.6%) in the 0.8 mg group and no patients in the 0.4 mg or placebo groups discontinuing treatment due to abnormal ejaculation.

Laboratory Tests No laboratory test interactions with tamsulosin hydrochloride capsules are known. Treatment with tamsulosin hydrochloride capsules for up to 12 months had no significant effect on prostate-specific antigen (PSA).

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of tamsulosin hydrochloride capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to tamsulosin hydrochloride capsules. Allergic-type reactions such as skin rash, urticaria, pruritus, angioedema, and respiratory symptoms have been reported with positive rechallenge in some cases.

Priapism has been reported rarely. Infrequent reports of dyspnea, palpitations, hypotension, atrial fibrillation, arrhythmia, tachycardia, skin desquamation including reports of Stevens-Johnson syndrome, erythema multiforme, dermatitis exfoliative, constipation, vomiting, dry mouth, visual impairment, and epistaxis have been received during the postmarketing period.

During cataract and glaucoma surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha 1 blocker therapy [see Warnings and Precautions (5.5)].

Adverse reaction frequency tables (US label) US FDA label
Table 1: Treatment-Emergent A treatment-emergent adverse event was defined as any event satisfying one of the following criteria: The adverse event occurred for the first time after initial dosing with double-blind study medication;The adverse event was present prior to or at the time of initial dosing with double-blind study medication and subsequently increased in severity during double-blind treatment; or The adverse event was present prior to or at the time of initial dosing with double-blind study medication, disappeared completely, and then reappeared during double-blind treatment.Adverse Events Occurring in ≥2% of Tamsulosin Hydrochloride Capsules or Placebo Patients in Two U.S. Short-Term Placebo-Controlled Clinical Studies
BODY SYSTEM/ ADVERSE EVENT TAMSULOSIN HYDROCHLORIDE CAPSULES GROUPS PLACEBO
0.4 mg n=502 0.8 mg n=492 n=493
BODY AS WHOLE
Headache 97 (19.3%) 104 (21.1%) 99 (20.1%)
Infection Coding preferred terms also include cold, common cold, head cold, flu, and flu-like symptoms. 45 (9.0%) 53 (10.8%) 37 (7.5%)
Asthenia 39 (7.8%) 42 (8.5%) 27 (5.5%)
Back pain 35 (7.0%) 41 (8.3%) 27 (5.5%)
Chest pain 20 (4.0%) 20 (4.1%) 18 (3.7%)
NERVOUS SYSTEM
Dizziness 75 (14.9%) 84 (17.1%) 50 (10.1%)
Somnolence 15 (3.0%) 21 (4.3%) 8 (1.6%)
Insomnia 12 (2.4%) 7 (1.4%) 3 (0.6%)
Libido decreased 5 (1.0%) 10 (2.0%) 6 (1.2%)
RESPIRATORY SYSTEM
Rhinitis Coding preferred terms also include nasal congestion, stuffy nose, runny nose, sinus congestion, and hay fever. 66 (13.1%) 88 (17.9%) 41 (8.3%)
Pharyngitis 29 (5.8%) 25 (5.1%) 23 (4.7%)
Cough increased 17 (3.4%) 22 (4.5%) 12 (2.4%)
Sinusitis 11 (2.2%) 18 (3.7%) 8 (1.6%)
DIGESTIVE SYSTEM
Diarrhea 31 (6.2%) 21 (4.3%) 22 (4.5%)
Nausea 13 (2.6%) 19 (3.9%) 16 (3.2%)
Tooth disorder 6 (1.2%) 10 (2.0%) 7 (1.4%)
UROGENITAL SYSTEM
Abnormal ejaculation 42 (8.4%) 89 (18.1%) 1 (0.2%)
SPECIAL SENSES
Blurred vision 1 (0.2%) 10 (2.0%) 2 (0.4%)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Tamsulosin hydrochloride capsules are not indicated for use in women. There are no adequate data on the developmental risk associated with the use of tamsulosin hydrochloride capsules in pregnant women. No adverse developmental effects were observed in animal studies in which tamsulosin hydrochloride was administered to rats or rabbits during the period of organogenesis (GD 7 to 17 in the rat and GD 6 to 18 in the rabbit) [see Data].

In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. Data Administration of tamsulosin hydrochloride to pregnant female rats during the period of organogenesis at dose levels up to approximately 50 times the human therapeutic AUC exposure (300 mg/kg/day) revealed no evidence of harm to the fetus.

Administration of tamsulosin hydrochloride to pregnant rabbits during the period of organogenesis at dose levels up to 50 mg/kg/day produced no evidence of fetal harm.

Mechanism of action

12.1 Mechanism of Action The symptoms associated with benign prostatic hyperplasia (BPH) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma.

However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck leading to constriction of the bladder outlet. Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha 1 adrenoceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra, and bladder neck.

Blockade of these adrenoceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in symptoms of BPH. Tamsulosin, an alpha 1 adrenoceptor blocking agent, exhibits selectivity for alpha 1 receptors in the human prostate. At least three discrete alpha 1 adrenoceptor subtypes have been identified: alpha 1A, alpha 1B, and alpha 1D; their distribution differs between human organs and tissue.

Approximately 70% of the alpha 1 receptors in the human prostate are of the alpha 1A subtype. Tamsulosin hydrochloride capsules are not intended for use as an antihypertensive drug.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Urologic pharmacodynamic effects have been evaluated in neurologically impaired pediatric patients and in adults with BPH [see Use in Specific Populations (8.4) and Clinical Studies (14)].

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Tamsulosin hydrochloride is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged.

The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion.

Excretion On administration of the radiolabeled dose of tamsulosin hydrochloride to 4 healthy volunteers, 97% of the administered radioactivity was recovered, with urine (76%) representing the primary route of excretion compared to feces (21%) over 168 hours.

Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.

Because of absorption rate-controlled pharmacokinetics with tamsulosin hydrochloride capsules, the apparent half-life of tamsulosin hydrochloride is approximately 9 to 13 hours in healthy volunteers and 14 to 15 hours in the target population.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The pharmacokinetics of tamsulosin hydrochloride have been evaluated in adult healthy volunteers and patients with BPH after single and/or multiple administration with doses ranging from 0.1 mg to 1 mg. Absorption Absorption of tamsulosin hydrochloride from tamsulosin hydrochloride capsules 0.4 mg is essentially complete (>90%) following oral administration under fasting conditions.

Tamsulosin hydrochloride exhibits linear kinetics following single and multiple dosing, with achievement of steady-state concentrations by the fifth day of once-a-day dosing. Effect of Food The time to maximum concentration (T max) is reached by 4 to 5 hours under fasting conditions and by 6 to 7 hours when tamsulosin hydrochloride capsules are administered with food.

Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max) compared to fed conditions (Figure 1). Figure 1: Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) The effects of food on the pharmacokinetics of tamsulosin hydrochloride are consistent regardless of whether a tamsulosin hydrochloride capsule is taken with a light breakfast or a high-fat breakfast (Table 2).

Table 2: Mean (± S.D.) Pharmacokinetic Parameters Following Tamsulosin Hydrochloride Capsules 0.4 mg Once Daily or 0.8 mg Once Daily with a Light Breakfast, High-Fat Breakfast or Fasted Pharmacokinetic Parameter 0.4 mg QD to healthy volunteers; n=23 (age range 18–32 years) 0.8 mg QD to healthy volunteers; n=22 (age range 55–75 years) Light Breakfast Fasted Light Breakfast High-Fat Breakfast Fasted C min = observed minimum concentration C max = observed maximum tamsulosin hydrochloride plasma concentration T max = median time-to-maximum concentration T 1/2 = observed half-life AUC τ = area under the tamsulosin hydrochloride plasma time curve over the dosing interval C min (ng/mL) 4.0 ± 2.6 3.8 ± 2.5 12.3 ± 6.7 13.5 ± 7.6 13.3 ± 13.3 C max (ng/mL) 10.1 ± 4.8 17.1 ± 17.1 29.8 ± 10.3 29.1 ± 11.0 41.6 ± 15.6 C max /C min Ratio 3.1 ± 1.0 5.3 ± 2.2 2.7 ± 0.7 2.5 ± 0.8 3.6 ± 1.1 T max (hours) 6.0 4.0 7.0 6.6 5.0 T 1/2 (hours) - - - - 14.9 ± 3.9 AUC τ (ng∙hr/mL) 151 ± 81.5 199 ± 94.1 440 ± 195 449 ± 217 557 ± 257 Distribution The mean steady-state apparent volume of distribution of tamsulosin hydrochloride after intravenous administration to 10 healthy male adults was 16 L, which is suggestive of distribution into extracellular fluids in the body. Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).

The results of two-way in vitro studies indicate that the binding of tamsulosin hydrochloride to human plasma proteins is not affected by amitriptyline, diclofenac, glyburide, simvastatin plus simvastatin-hydroxy acid metabolite, warfarin, diazepam, propranolol, trichlormethiazide, or chlormadinone. Likewise, tamsulosin hydrochloride had no effect on the extent of binding of these drugs.

Metabolism There is no enantiomeric bioconversion from tamsulosin hydrochloride [R(-) isomer] to the S(+) isomer in humans. Tamsulosin hydrochloride is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. However, the pharmacokinetic profile of the metabolites in humans has not been established.

Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6 as well as via some minor participation of other CYP isoenzymes. Inhibition of hepatic drug-metabolizing enzymes may lead to increased exposure to tamsulosin [see Warnings and Precautions (5.2) and Drug Interactions (7.1)]. The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion.

Incubations with human liver microsomes showed no evidence of clinically significant metabolic interactions between tamsulosin hydrochloride and amitriptyline, albuterol (beta agonist), glyburide (glibenclamide) and finasteride (5-alpha-reductase inhibitor for treatment of BPH). However, results of the in vitro testing of the tamsulosin hydrochloride interaction with diclofenac and warfarin were equivocal.

Excretion On administration of the radiolabeled dose of tamsulosin hydrochloride to 4 healthy volunteers, 97% of the administered radioactivity was recovered, with urine (76%) representing the primary route of excretion compared to feces (21%) over 168 hours. Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.

Because of absorption rate-controlled pharmacokinetics with tamsulosin hydrochloride capsules, the apparent half-life of tamsulosin hydrochloride is approximately 9 to 13 hours in healthy volunteers and 14 to 15 hours in the target population. Tamsulosin hydrochloride undergoes restrictive clearance in humans, with a relatively low systemic clearance (2.88 L/h).

Specific Populations Pediatric use Tamsulosin hydrochloride capsules are not indicated for use in pediatric populations [see Use in Specific Populations (8.4)]. Geriatric (age) use Cross-study comparison of tamsulosin hydrochloride capsules overall exposure (AUC) and half-life indicates that the pharmacokinetic disposition of tamsulosin hydrochloride may be slightly prolonged in geriatric males compared to young, healthy male volunteers.

Intrinsic clearance is independent of tamsulosin hydrochloride binding to AAG, but diminishes with age, resulting in a 40% overall higher exposure (AUC) in subjects of age 55 to 75 years compared to subjects of age 20 to 32 years [see Use in Specific Populations (8.5)]. Renal impairment The pharmacokinetics of tamsulosin hydrochloride have been compared in 6 subjects with mild-moderate (30≤ CL cr <70 mL/min/1.73 m²) or moderate-severe (10≤ CL cr <30 mL/min/1.73 m²) renal impairment and 6 normal subjects (CL cr >90 mL/min/1.73 m²).

While a change in the overall plasma concentration of tamsulosin hydrochloride was observed as the result of altered binding to AAG, the unbound (active) concentration of tamsulosin hydrochloride, as well as the intrinsic clearance, remained relatively constant. Therefore, patients with renal impairment do not require an adjustment in Tamsulosin hydrochloride capsules dosing.

However, patients with end-stage renal disease (CL cr <10 mL/min/1.73 m²) have not been studied [see Use in Specific Populations (8.6)]. Hepatic impairment The pharmacokinetics of tamsulosin hydrochloride have been compared in 8 subjects with moderate hepatic impairment (Child-Pugh's classification: Grades A and B) and 8 normal subjects.

While a change in the overall plasma concentration of tamsulosin hydrochloride was observed as the result of altered binding to AAG, the unbound (active) concentration of tamsulosin hydrochloride does not change significantly, with only a modest (32%) change in intrinsic clearance of unbound tamsulosin hydrochloride. Therefore, patients with moderate hepatic impairment do not require an adjustment in tamsulosin hydrochloride capsules dosage.

Tamsulosin hydrochloride capsules have not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)]. Drug Interactions Cytochrome P450 inhibition Strong and moderate inhibitors of CYP3A4 or CYP2D6 The effects of ketoconazole (a strong inhibitor of CYP3A4) at 400 mg once daily for 5 days on the pharmacokinetics of a single tamsulosin hydrochloride capsule 0.4 mg dose was investigated in 24 healthy volunteers (age range 23 to 47 years).

Concomitant treatment with ketoconazole resulted in an increase in the C max and AUC of tamsulosin by a factor of 2.2 and 2.8, respectively [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of tamsulosin hydrochloride capsules have not been evaluated [see Warnings and Precautions (5.2) and Drug Interactions (7.1)].

The effects of paroxetine (a strong inhibitor of CYP2D6) at 20 mg once daily for 9 days on the pharmacokinetics of a single tamsulosin hydrochloride capsule 0.4 mg dose was investigated in 24 healthy volunteers (age range 23 to 47 years). Concomitant treatment with paroxetine resulted in an increase in the C max and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively [see Warnings and Precautions (5.2) and Drug Interactions (7.1)].

A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM). A fraction of the population (about 7% of Caucasians and 2% of African Americans) are CYP2D6 PMs. Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when tamsulosin hydrochloride capsules 0.4 mg are co-administered with strong CYP3A4 inhibitors in CYP2D6 PMs, tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions (5.2) and Drug Interactions (7.1)].

The effects of concomitant administration of a moderate CYP2D6 inhibitor (e.g., terbinafine) on the pharmacokinetics of tamsulosin hydrochloride capsules have not been evaluated [see Warnings and Precautions (5.2) and Drug Interactions (7.1)]. The effects of co-administration of both a CYP3A4 and a CYP2D6 inhibitor with tamsulosin hydrochloride capsules have not been evaluated.

However, there is a potential for significant increase in tamsulosin exposure when tamsulosin hydrochloride capsules 0.4 mg are co-administered with a combination of both CYP3A4 and CYP2D6 inhibitors [see Warnings and Precautions (5.2) and Drug Interactions (7.1)]. Cimetidine The effects of cimetidine at the highest recommended dose (400 mg every 6 hours for 6 days) on the pharmacokinetics of a single tamsulosin hydrochloride capsule 0.4 mg dose was investigated in 10 healthy volunteers (age range 21 to 38 years).

Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of tamsulosin hydrochloride, which resulted in a moderate increase in tamsulosin hydrochloride AUC (44%) [see Warnings and Precautions (5.2) and Drug Interactions (7.1)]. Other alpha adrenergic blocking agents The pharmacokinetic and pharmacodynamic interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents have not been determined; however, interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents may be expected [see Warnings and Precautions (5.2) and Drug Interactions (7.2)].

PDE5 inhibitors Caution is advised when alpha adrenergic blocking agents, including tamsulosin hydrochloride, are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Warnings and Precautions (5.2) and Drug Interactions (7.3)].

Warfarin A definitive drug-drug interaction study between tamsulosin hydrochloride and warfarin was not conducted. Results from limited in vitro and in vivo studies are inconclusive. Therefore, caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Warnings and Precautions (5.2) and Drug Interactions (7.4)].

Nifedipine, atenolol, enalapril In three studies in hypertensive subjects (age range 47 to 79 years) whose blood pressure was controlled with stable doses of nifedipine, atenolol, or enalapril for at least 3 months, tamsulosin hydrochloride capsules 0.4 mg for 7 days followed by tamsulosin hydrochloride capsules 0.8 mg for another 7 days (n=8 per study) resulted in no clinically significant effects on blood pressure and pulse rate compared to placebo (n=4 per study). Therefore, dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see Drug Interactions (7.5)].

Digoxin and theophylline In two studies in healthy volunteers (n=10 per study; age range 19 to 39 years) receiving tamsulosin hydrochloride capsules 0.4 mg/day for 2 days, followed by tamsulosin hydrochloride capsules 0.8 mg/day for 5 to 8 days, single intravenous doses of digoxin 0.5 mg or theophylline 5 mg/kg resulted in no change in the pharmacokinetics of digoxin or theophylline. Therefore, dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Drug Interactions (7.6)].

Furosemide The pharmacokinetic and pharmacodynamic interaction between tamsulosin hydrochloride capsules 0.8 mg/day (steady-state) and furosemide 20 mg intravenously (single dose) was evaluated in 10 healthy volunteers (age range 21 to 40 years). Tamsulosin hydrochloride capsules had no effect on the pharmacodynamics (excretion of electrolytes) of furosemide.

While furosemide produced an 11% to 12% reduction in tamsulosin hydrochloride C max and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the tamsulosin hydrochloride capsules dosage [see Drug Interactions (7.7)]. Figure 1

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Tamsulosin 200 mcg Capsule₱11.60–₱28.00Reference ₱17.50per capsuleDPRI procurement range
Tamsulosin 200 mcg Orally Disintegrating Tablet₱10.50–₱38.49Reference ₱21.00per tabletDPRI procurement range
Tamsulosin 400 mcg MR Film Coated Tablet₱4.99–₱21.00Reference ₱14.73per tabletDPRI procurement range
200 mcg (as hydrochloride) capsule₱47.00per capsulePhilHealth GAMOT fixed fee
200 mcg orally disintegrating tablet₱10.50per tabletPhilHealth GAMOT fixed fee
400 mcg prolonged release film coated tablet₱30.50per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Tamsulosin
PNF listingOral: 200 micrograms capsule (as hydrochloride)
PNF listingOral: 200 mcg orally disintegrating tablet
PNF listingOral: 400 mcg prolonged release film coated tablet
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Tamsulosin hydrochloride · Synthon B.V. [US FDA-approved label, version 9, October 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13a5032d-0be1-4001-916e-459f0b1a051d
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .